IP Verse

Polpharma Biologics competitive analysis

Loading summary...

Explore patent oppositions filed by Polpharma Biologics against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 6, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3359572	Method For Treating Multiple Sclerosis	F HOFFMANN LA ROCHE	Aug 26, 2025
EP4152004	Assay For Jc Virus Antibodies	BIOGEN MA	Aug 19, 2025
EP3237004	Predicting Outcome Of Treatment With An Anti- 4 7 Integrin Antibody	MILLENNIUM PHARMACEUTICALS	Feb 7, 2025
EP3339865	Assay For Jc Virus Antibodies	BIOGEN MA	May 23, 2023
EP3575792	Method Of Assessing Risk Of Pml	BIOGEN MA	Dec 1, 2022
EP3095463	Methods For Treating Progressive Multiple Sclerosis	F HOFFMANN LA ROCHE	Jun 8, 2021
EP3264094	Methods For Evaluating An Immune Response To A Therapeutic Agent	BIOGEN MA	May 18, 2021
EP2676967	Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab	BIOGEN IDEC MA	May 14, 2020
EP2715352	Method Of Assessing Risk Of Pml	BIOGEN IDEC MA	Jan 17, 2020

Discover the latest PTAB cases involving Polpharma Biologics, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Polpharma Biologics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
POLPHARMA BIOLOGICS	9	-	-	-
BIOGEN IDEC MA	-	30	-	1
BIOGEN MA	-	52	-	7
F HOFFMANN LA ROCHE	16	140	-	-